Masoud Azodi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Masoud Azodi has a total of 292 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Davide Santin
Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA
29 shared publications - Peter E. Schwartz
Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06510
29 shared publications - Stefania Bellone
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut
22 shared publications - Elena Ratner
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut
21 shared publications - Gary Altwerger
Yale University School of Medicine, New Haven, CT, USA
14 shared publications - Natalia Buza
Department of Pathology, Yale School of Medicine, New Haven, Connecticut
13 shared publications
Latest Publications
- 5 February 2026
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 33 (7) , 978-986
Efficacy of Laparoscopic-Assisted Transversus Abdominus Plane (LA-TAP) Block for Minimally Invasive Gynecologic Surgeries (MIGS): A Randomized Controlled Trial
- 5 February 2026
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 33 (7) , 978-986
Efficacy of Laparoscopic-Assisted Transversus Abdominus Plane (LA-TAP) Block for Minimally Invasive Gynecologic Surgeries (MIGS): A Randomized Controlled Trial
- 20 December 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (6) , 104440
Association of platinum-based chemotherapy with survival in ovarian carcinosarcoma: a retrospective 2-center cohort study
- 20 December 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (6) , 104440
Association of platinum-based chemotherapy with survival in ovarian carcinosarcoma: a retrospective 2-center cohort study
- 25 January 2025
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 32 (6) , 534-539.e5
Time for Educational Revamp? A Nationwide Survey of Fellowships in Minimally Invasive Gynecologic Surgery Program Directors’ and Fellows’ Didactic Experiences
- 25 January 2025
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 32 (6) , 534-539.e5
Time for Educational Revamp? A Nationwide Survey of Fellowships in Minimally Invasive Gynecologic Surgery Program Directors’ and Fellows’ Didactic Experiences
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Representativeness of Study Participants
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Representativeness of Study Participants
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Representative microscopic images of paired cervical biopsies at enrollment at 6 months follow-up.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Representative microscopic images of paired cervical biopsies at enrollment at 6 months follow-up.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Representativeness of Study Participants
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Representativeness of Study Participants
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Representative microscopic images of paired cervical biopsies at enrollment at 6 months follow-up.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Representative microscopic images of paired cervical biopsies at enrollment at 6 months follow-up.
- 9 April 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (9) , 1768-1777
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Purpose: We report the results of a randomized phase II trial of imiquimod, a topical immune-response modulator versus imiquimod plus a 9-valent human papillomavirus (HPV) vaccine (9vHPV) versus clinical surveillance in cervical intraepithelial neoplasia (CIN2/3) patients. Patients and Methods: We randomly allocated 133 patients with untreated CIN2/3 in equal proportions to a 4-month treatment with self-applied vaginal suppositories containing imiquimod (Arm B) or imiquimod plus a 9vHPV (Arm C) versus clinical surveillance (Arm A). The main outcome was efficacy, defined as histologic regression to CIN1 or less. Secondary outcomes were HPV clearance and tolerability. Exploratory objectives included the comparison of cervical CD4/CD8 T-cell infiltration at baseline, mid-study, and posttreatment by flow cytometry among study arms. Results: Of the 114 evaluable patients 77% and 23% harbored CIN2 and CIN3, respectively. Regression to CIN1 or less was observed in 95% of patients in the imiquimod group (Arm B) compared with 79% in the control/surveillance (Arm A); P = 0.043 and 84% in the imiquimod+9vHPV group (Arm C; P = 0.384 vs. Arm A). Neither of the treatment-arm differences from Arm A reached the prespecified α = 0.025 significance level. No significant differences were noted in the secondary outcome of rate of HPV clearance. The number of tissue-resident memory CD4/CD8 T cells in cytobrush samples demonstrated a >5-fold increase in Arm B/imiquimod when compared with Arm A/surveillance (P < 0.01). In contrast, there was no significant difference in T-cell responses among participants in Arm C when compared with Arm A. Imiquimod treatment was well tolerated. Conclusions: Although imiquimod induced a higher regression to CIN1 or less and significant increases in CD4/CD8 T cells infiltrating the cervix, it did not meet its prespecified statistical outcome for efficacy. A higher regression rate than expected was observed in the surveillance arm of this prospective trial. Future clinical trials with imiquimod targeting CIN3 patients are warranted.
- 9 April 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (9) , 1768-1777
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Purpose: We report the results of a randomized phase II trial of imiquimod, a topical immune-response modulator versus imiquimod plus a 9-valent human papillomavirus (HPV) vaccine (9vHPV) versus clinical surveillance in cervical intraepithelial neoplasia (CIN2/3) patients. Patients and Methods: We randomly allocated 133 patients with untreated CIN2/3 in equal proportions to a 4-month treatment with self-applied vaginal suppositories containing imiquimod (Arm B) or imiquimod plus a 9vHPV (Arm C) versus clinical surveillance (Arm A). The main outcome was efficacy, defined as histologic regression to CIN1 or less. Secondary outcomes were HPV clearance and tolerability. Exploratory objectives included the comparison of cervical CD4/CD8 T-cell infiltration at baseline, mid-study, and posttreatment by flow cytometry among study arms. Results: Of the 114 evaluable patients 77% and 23% harbored CIN2 and CIN3, respectively. Regression to CIN1 or less was observed in 95% of patients in the imiquimod group (Arm B) compared with 79% in the control/surveillance (Arm A); P = 0.043 and 84% in the imiquimod+9vHPV group (Arm C; P = 0.384 vs. Arm A). Neither of the treatment-arm differences from Arm A reached the prespecified α = 0.025 significance level. No significant differences were noted in the secondary outcome of rate of HPV clearance. The number of tissue-resident memory CD4/CD8 T cells in cytobrush samples demonstrated a >5-fold increase in Arm B/imiquimod when compared with Arm A/surveillance (P < 0.01). In contrast, there was no significant difference in T-cell responses among participants in Arm C when compared with Arm A. Imiquimod treatment was well tolerated. Conclusions: Although imiquimod induced a higher regression to CIN1 or less and significant increases in CD4/CD8 T cells infiltrating the cervix, it did not meet its prespecified statistical outcome for efficacy. A higher regression rate than expected was observed in the surveillance arm of this prospective trial. Future clinical trials with imiquimod targeting CIN3 patients are warranted.